查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953414

披衣菌感染感染診斷市場 - 全球產業規模、佔有率、趨勢、機會及預測（按檢測類型、感染類型、最終用戶、地區和競爭格局分類，2021-2031年）

Chlamydia Infection Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Type of Infections, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球沙眼衣原體感染診斷市場預計將從 2025 年的 7.7112 億美元成長到 2031 年的 11.3599 億美元，複合年成長率為 6.67%。

這些診斷方法主要透過檢查室分析和快速檢測套組進行，利用核酸增幅檢查(NAT) 技術檢測患者檢體中的披衣菌感染衣原體。市場成長的促進因素包括全球性行為感染傳染病的持續流行以及各國政府為確保早期發現而大力推行的篩檢。例如，美國疾病管制與預防中心 (CDC) 發布的初步數據顯示，2024 年美國約有 150 萬例披衣菌感染病例，這凸顯了儘管年度感染率有所波動，但有效檢測的必要性依然存在。

市場概覽
預測期 2027-2031
市場規模：2025年 7.7112億美元
市場規模：2031年 1,135,990,000 美元
複合年成長率：2026-2031年 6.67%
成長最快的細分市場 醫院
最大的市場 北美洲

然而，沙眼衣原體感染面臨一個重大障礙，因為其通常無症狀，這降低了患者就醫的緊迫性。由於許多感染者沒有臨床症狀，他們往往得不到診斷和治療，這限制了每年進行的診斷檢測總數。這種情況導致人們更加依賴主動的公共衛生項目，而不是有症狀的患者就診，這限制了在常規篩檢尚未嚴格實施的地區市場成長。

市場促進因素

全球披衣菌感染衣原體感染疾病的不斷增加是推動市場成長的主要因素，因此需要強力的監測來遏制這種廣泛傳播的細菌。隨著感染病例的持續增加，醫療系統正著力進行廣泛的篩檢，以發現未接受治療的感染者並預防不孕症等併發症，從而對頻繁的檢查室檢測產生了持續的需求。根據 MedTech Dive 2025 年 3 月發表的一篇報導《FDA核准首批三種性行為感染(STI) 家用檢測套組》，美國疾病管制與預防中心 (CDC) 的數據顯示，2023 年美國報告的梅毒、淋病和披衣菌感染病例超過 240 萬例，凸顯了持續監測的必要性。同樣，英國衛生安全局 (UKHSA) 2025 年 12 月的一份報告指出，2024 年英格蘭對 15 至 24 歲的年輕女性進行了 601,295 次披衣菌感染檢測，這表明英國開展了大規模的國家篩檢工作。

此外，快速照護現場(POC) 技術的進步和家用檢測套組需求的不斷成長，正透過分散式醫療服務管道改變市場格局。這些創新克服了隱私和便利性方面的障礙，鼓勵那些原本可能避免去診所就診的人尋求診斷，同時監管機構也日益認可這些解決方案的有效性，並推動其更廣泛應用。根據 CIDRAP 於 2025 年 3 月報道，美國食品藥物管理局(FDA)核准了首批由 Visby Medical 開發的商用家用檢測套組，用於檢測披衣菌感染、淋病和滴蟲病。這種以使用者為主導的檢測方式，透過識別傳統臨床方法難以發現的無症狀感染者，提高了檢測率。

市場挑戰

全球沙眼衣原體感染診斷市場面臨的主要障礙之一是該感染通常無症狀，這抑制了人們自願檢測的動機。大多數感染者不會出現明顯症狀，因此缺乏立即就醫或接受篩檢的動機。這種缺乏緊迫感的情況顯著降低了患者主導就診的次數，迫使市場更依賴政府資助的篩檢項目，而非消費者的自發性需求。因此，在公共衛生資源有限或篩檢強制措施執行不力的地區，檢測量會急劇下降，直接限制診斷試劑生產商的收入潛力。

近期監測數據印證了這一趨勢，顯示檢測活動的減少導致檢出率下降。例如，英國衛生安全局報告稱，2025年披衣菌感染的診斷數量比2024年下降了13%。這一下降主要是由於年輕人檢測量的減少所致。這種下降趨勢凸顯了缺乏臨床症狀如何導致感染未被發現，從而有效地縮小了診斷檢測解決方案的潛在市場。

市場趨勢

多重核酸增幅檢查擴增檢測 (MNA) 的廣泛應用正在重塑診斷流程，它能夠同時檢測披衣菌感染披衣菌和伴隨感染疾病，例如淋病奈瑟菌和陰道毛滴蟲。這一趨勢滿足了臨床對全面性健康評估的需求，與單標靶檢測相比，單次檢測即可識別多種病原體，從而改善患者管理和檢查室效率。 Hologic 公司在 2025 年 11 月發布的 2025 會計年度第四季財報中報告稱，其分子診斷業務收入成長了 1.2%。這一成長主要得益於先進多重檢測板（例如 BV CV/TV 檢測）的廣泛應用，該檢測板在一個自動化平台上整合了陰道炎和性行為感染病原體的檢測。

同時，以藥局為基礎的去中心化篩檢模式的興起，正在透過將診斷服務引入本地零售環境，重新定義病患的就醫途徑，消除了以往就醫的障礙。公共衛生計畫正利用社區藥局分發自取樣試劑盒，並推廣即時干預，從而有效地涵蓋那些可能不會定期就醫的無症狀人群。例如，2025年2月，薩裡郡議會在其「2025-2028年披衣菌感染治療和篩檢」協議中正式規定了服務規範，要求社區藥屋主動向25歲以下性活躍人群提供披衣菌感染檢測套組。這凸顯了感染率管理方面向以藥房為主導的基礎設施的策略轉變。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球披衣菌感染感染診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依檢測方法（培養試驗、核酸增幅檢查（NAAT）、直接螢光抗體試驗、血清學試驗、其他）
    • 依感染部位分類（生殖器沙眼衣原體感染、直腸沙眼衣原體感染、眼部沙眼衣原體感染）
    • 依最終使用者（醫院、專科診所、診斷中心）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美披衣菌感染感染診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲披衣菌感染感染診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區披衣菌感染感染診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲披衣菌感染感染診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美披衣菌感染感染診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球披衣菌感染感染診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc
  • Quidel Corporation
  • DiaSorin SpA
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Limited
  • bioMerieux SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15821

The Global Chlamydia Infection Diagnostics Market is projected to expand from USD 771.12 Million in 2025 to USD 1135.99 Million by 2031, reflecting a CAGR of 6.67%. These diagnostics primarily involve laboratory assays and rapid testing kits that use Nucleic Acid Amplification Tests to detect Chlamydia trachomatis in patient samples. Market growth is underpinned by the continuing global prevalence of sexually transmitted infections and strong government mandates for screening to ensure early detection. For instance, the Centers for Disease Control and Prevention reported provisional data showing approximately 1.5 million chlamydia cases in the U.S. in 2024, highlighting the persistent need for effective testing despite variations in annual infection rates.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 771.12 Million
Market Size 2031USD 1135.99 Million
CAGR 2026-20316.67%
Fastest Growing SegmentHospitals
Largest MarketNorth America

However, the market faces a significant hurdle due to the frequently asymptomatic nature of chlamydia, which reduces the urgency for patients to seek medical advice. Since many infected individuals show no clinical symptoms, they often go undiagnosed and untreated, which limits the total number of diagnostic tests conducted each year. This situation creates a reliance on proactive public health programs rather than symptomatic patient visits, thereby restricting market growth in areas where routine screening is not rigorously enforced.

Market Driver

The rising global incidence of Chlamydia trachomatis infections serves as a major market driver, requiring strong surveillance to control the spread of this widespread bacterium. As transmission continues, healthcare systems are emphasizing broad screening to detect untreated individuals and prevent complications like infertility, fueling a steady demand for high-volume laboratory testing. According to a March 2025 MedTech Dive article titled "FDA OKs first at-home test for 3 STIs," CDC data revealed that over 2.4 million cases of syphilis, gonorrhea, and chlamydia were reported in the U.S. in 2023, reinforcing the necessity for ongoing monitoring. Similarly, the UK Health Security Agency's December 2025 report noted that 601,295 chlamydia tests were conducted on young women aged 15 to 24 in England during 2024, demonstrating the vast scale of national screening efforts.

Additionally, the growth of rapid Point-of-Care (POC) technologies and the increasing demand for at-home testing kits are transforming the market by decentralizing care access. These innovations overcome barriers regarding privacy and convenience, prompting individuals who might avoid clinics to seek diagnosis, while regulatory agencies are increasingly validating these solutions for wider use. As reported by CIDRAP in March 2025, the U.S. FDA authorized the first over-the-counter, at-home test from Visby Medical that detects chlamydia, gonorrhea, and trichomoniasis. This move toward user-initiated testing improves detection rates by identifying asymptomatic cases often missed by traditional clinical methods.

Market Challenge

A major obstacle hindering the Global Chlamydia Infection Diagnostics Market is the often asymptomatic nature of the infection, which discourages voluntary testing. Since most infected individuals lack noticeable symptoms, they feel little immediate motivation to seek medical care or undergo screening. This lack of urgency significantly lowers the volume of patient-initiated visits, making the market heavily reliant on government-funded screening programs rather than organic consumer demand. Consequently, when public health resources are limited or screening mandates are not strictly enforced, testing numbers fall sharply, directly restricting the revenue potential for diagnostic manufacturers.

Recent surveillance data confirms this trend, showing that decreased testing activity leads to lower detection rates. For example, the UK Health Security Agency reported in 2025 that chlamydia diagnoses dropped by 13 percent in 2024 compared to the prior year, a decline largely driven by reduced testing volumes among young adults. This contraction illustrates how the lack of clinical symptoms allows infections to remain undetected, effectively reducing the addressable market for diagnostic testing solutions.

Market Trends

The widespread adoption of Multiplex Nucleic Acid Amplification Assays is reshaping diagnostic workflows by allowing the simultaneous detection of Chlamydia trachomatis and co-infections like Neisseria gonorrhoeae and Trichomonas vaginalis. This trend meets the clinical need for comprehensive sexual health profiling, as identifying multiple pathogens in a single test enhances patient management and laboratory efficiency compared to single-target tests. In its "Financial Results for Fourth Quarter of Fiscal 2025" released in November 2025, Hologic, Inc. reported a 1.2 percent increase in molecular diagnostics revenue, a growth attributed to the rising use of their advanced multiplex panels, such as the BV CV/TV assays, which consolidate testing for vaginitis and sexually transmitted pathogens on automated platforms.

Concurrently, the rise of decentralized pharmacy-based screening models is redefining patient access by bringing diagnostic services into community retail environments, thereby eliminating obstacles associated with traditional clinical visits. Public health programs are increasingly leveraging local pharmacies to distribute self-collection kits and facilitate immediate intervention, effectively reaching asymptomatic populations who might otherwise skip routine medical appointments. For instance, in February 2025, Surrey County Council formalized a service specification in its "Chlamydia Treatment and Screening 2025-28" agreement, requiring community pharmacies to actively provide chlamydia screening kits to sexually active individuals under 25, highlighting the strategic pivot toward pharmacy-led infrastructure in managing infection rates.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc
  • Quidel Corporation
  • DiaSorin SpA
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Limited
  • bioMerieux SA

Report Scope

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chlamydia Infection Diagnostics Market, By Test Type

  • Culture Test
  • Nucleic Acid Amplification Test (NAAT)
  • Direct Fluorescent Antibody Test
  • Serology Test and Other

Chlamydia Infection Diagnostics Market, By Type of Infections

  • Genital Chlamydia Infection
  • Rectal Chlamydia Infection
  • Ocular Chlamydia Infection

Chlamydia Infection Diagnostics Market, By End User

  • Hospitals
  • Specialty Clinics
  • Diagnostics Centre

Chlamydia Infection Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chlamydia Infection Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other)
    • 5.2.2. By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)
    • 5.2.3. By End User (Hospitals, Specialty Clinics, Diagnostics Centre)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Chlamydia Infection Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Type of Infections
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chlamydia Infection Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Type of Infections
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Chlamydia Infection Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Type of Infections
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Chlamydia Infection Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Type of Infections
        • 6.3.3.2.3. By End User

7. Europe Chlamydia Infection Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Type of Infections
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chlamydia Infection Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Type of Infections
        • 7.3.1.2.3. By End User
    • 7.3.2. France Chlamydia Infection Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Type of Infections
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Chlamydia Infection Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Type of Infections
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Chlamydia Infection Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Type of Infections
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Chlamydia Infection Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Type of Infections
        • 7.3.5.2.3. By End User

8. Asia Pacific Chlamydia Infection Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Type of Infections
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chlamydia Infection Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Type of Infections
        • 8.3.1.2.3. By End User
    • 8.3.2. India Chlamydia Infection Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Type of Infections
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Chlamydia Infection Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Type of Infections
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Chlamydia Infection Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Type of Infections
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Chlamydia Infection Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Type of Infections
        • 8.3.5.2.3. By End User

9. Middle East & Africa Chlamydia Infection Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Type of Infections
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chlamydia Infection Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Type of Infections
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Chlamydia Infection Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Type of Infections
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Chlamydia Infection Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Type of Infections
        • 9.3.3.2.3. By End User

10. South America Chlamydia Infection Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Type of Infections
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chlamydia Infection Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Type of Infections
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Chlamydia Infection Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Type of Infections
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Chlamydia Infection Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Type of Infections
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chlamydia Infection Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories
  • 15.3. Hologic, Inc.
  • 15.4. Becton, Dickinson and Company
  • 15.5. Bio-Rad Laboratories, Inc
  • 15.6. Quidel Corporation
  • 15.7. DiaSorin SpA
  • 15.8. AstraZeneca Plc
  • 15.9. Teva Pharmaceutical Industries Limited
  • 15.10. bioMerieux SA

16. Strategic Recommendations

17. About Us & Disclaimer